Sutro Biopharma, Inc. (STRO) analyst actions
Rating and price-target actions on STRO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the STRO overview →
3 measured STRO analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML | Press release | +0.00% | +5.97% | |
| Sutro Biopharma Announces Initiation of REFRaME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer | Press release | +0.00% | +0.22% | |
| Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial | Press release | -0.71% | -3.00% |
Keep exploring
More STRO: earnings → · SEC filings → · STRO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| InspireMD Inc. (NSPR) | 271 | 0.00% | 39% |
| Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) | 271 | -0.69% | 33% |
| PRESBIA PLC ORDINARY SHARES (LENS) | 270 | 0.00% | 42% |
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.